AshleyHall(Hall)ShoemakerMD

Pediatric Endocrinology • Nashville, TN

Pediatric Diabetes Endocrinology, Pediatric Obesity

Assistant Professor of Pediatrics, Vanderbilt University School of Medicine

Join to view full profile

Dr. Shoemaker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shoemaker's full profile

Already have an account?

Office
3601 21st Ave S
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-875-7633

Summary

I am a pediatric endocrinologist with an NIH funded research program focused on hypothalamic obesity including genetic disorders. I conduct translational research on the pathophysiology of hypothalamic obesity including phase 2-3 clinical trials. I also direct the VUMC Pediatric Prediabetes Clinic and the Prader-Willi Multispecialty Clinic.

Education & Training

Vanderbilt UniversityMS, Clinical Investigation, 2010 - 2012
Vanderbilt University Medical CenterFellowship, Pediatric Endocrinology, 2009 - 2012
Johns Hopkins UniversityResidency, Pediatrics, 2007 - 2009
Johns Hopkins UniversityInternship, Pediatrics, 2006 - 2007
Virginia Commonwealth University School of MedicineClass of 2006

Certifications & Licensure

TN State Medical License 2009 - 2026
AL State Medical License 2020 - 2020
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Endocrinology

Awards, Honors, & Recognition

Elected member Society for Pediatric Research, 2018
T2D Registry - Most Annual Updates Pediatric Diabetes Consortium, 2017-2018
T2D Registry - Highest Enrollment Pediatric Diabetes Consortium, 2016-2017
Early Investigators Award Endocrine Society, 2016
Join now to see all

Clinical Trials

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes Start of enrollment: 2011 Dec 02
Completed
Phase 3
Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome Start of enrollment: 2014 Apr 01
Completed
Phase 1, Phase 2
Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism Start of enrollment: 2014 Dec 01
Completed
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Start of enrollment: 2016 Mar 01
Completed
Phase 3
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers Start of enrollment: 2016 Sep 28
Completed
Vanderbilt Childhood Obesity Registry
ACTIVE_NOT_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism Start of enrollment: 2018 Sep 01
RECRUITING
PHASE2
A Study of GLWL-01 in Patients With Prader-Willi Syndrome Start of enrollment: 2018 Feb 20
Completed
Phase 2
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM Start of enrollment: 2018 Mar 20
Completed
Phase 3
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period Start of enrollment: 2018 Oct 01
Completed
Phase 3
Glucose Homeostasis in Pseudohypoparathyroidism Start of enrollment: 2019 Jun 19
Terminated
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity Start of enrollment: 2019 May 02
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

Prediction of resting energy expenditure for adolescents with severe obesity: A multi-centre analysis.
Amy A Rydin, Cameron Severn, Laura Pyle, Nazeen Morelli, Ashley H Shoemaker
Pediatric Obesity. 2024-07-01
7 citations
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial.
Christian L Roth, Cecilia Scimia, Ashley H Shoemaker, Michael Gottschalk, Jennifer Miller
The Lancet. Diabetes & Endocrinology. 2024-06-01
6 citations
Bardet-Biedl syndrome: A clinical overview focusing on diagnosis, outcomes and best-practice management.
Ashley Shoemaker
Diabetes, Obesity & Metabolism. 2024-04-01

Journal Articles

Diagnosis and Management of Pseudohypoparathyroidism and Related Disorders: First International Consensus Statement
Robert Pignolo, Ashley H Shoemaker, Michael A Levine, Nature

Press Mentions

Doctors Urged to Take More Active Role Against Childhood ObesityJanuary 11th, 2023
Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018November 15th, 2018
Cognition in Rare Hormonal DisorderFebruary 13th, 2018
Join now to see all

Grant Support

Phase 2 Study of Theophylline for the Treatment of PsuedohypoparathyroidismVANDERBILT UNIVERSITY MEDICAL CENTER2021–2025
Phase 2 Study of Theophylline for the Treatment of PsuedohypoparathyroidismVANDERBILT UNIVERSITY MEDICAL CENTER2021–2025
Phase 2 study of theophylline for the treatment of pseudohypoparathyroidismNIDDK2021–2025
Glucose homeostasis and beta cell function in pseudohypoparathyroidismNIDDK2019–2021
Clinical Scientist Development AwardDoris Duke Foundation2018–2021
Glucagon-like peptide-1 agonist effects on energy balance in hypothalamic obesityNIDDK2015–2019
K23 Mentored Career Development AwardNIDDK2014–2019

Committees

Member, Master of Science in Clinical Investigation Admissions Committee 2017 - Present
Member, Sleep Core Faculty Advisory Committee 2015 - Present
Member, Pediatric Endocrine Society Obesity Committee 2013 - Present